Proposed definition of ‘poor mobilizer’ in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo ItalianoTrapianto di Midollo Osseo
Open Access
- 30 May 2011
- journal article
- research article
- Published by Springer Science and Business Media LLC in Bone Marrow Transplantation
- Vol. 47 (3), 342-351
- https://doi.org/10.1038/bmt.2011.82
Abstract
Many lymphoma and myeloma patients fail to undergo ASCT owing to poor mobilization. Identification of poor mobilizers (PMs) would provide a tool for early intervention with new mobilization agents. The Gruppo italianoTrapianto di Midollo Osseo working group proposed a definition of PMs applicable to clinical trials and clinical practice. The analytic hierarchy process, a method for group decision making, was used in setting prioritized criteria. Lymphoma or myeloma patients were defined as ‘proven PM’ when: (1) after adequate mobilization (G-CSF 10 μg/kg if used alone or 5 μg/kg after chemotherapy) circulating CD34+ cell peak is 6 CD34+ cells per kg in 3 apheresis. Patients were defined as predicted PMs if: (1) they failed a previous collection attempt (not otherwise specified); (2) they previously received extensive radiotherapy or full courses of therapy affecting SC mobilization; and (3) they met two of the following criteria: advanced disease (2 lines of chemotherapy), refractory disease, extensive BM involvement or cellularity <30% at the time of mobilization; age 65 years. This definition of proven and predicted PMs should be validated in clinical trials and common clinical practice.This publication has 128 references indexed in Scilit:
- Management of poor peripheral blood stem cell mobilization: Incidence, predictive factors, alternative strategies and outcome. A retrospective analysis on 2177 patients from three major Italian institutionsTransfusion and Apheresis Science, 2009
- Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conferenceBlood, 2009
- Management strategies for poor peripheral blood stem cell mobilizationTransfusion and Apheresis Science, 2008
- A unified definition of clinical resistance/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working groupLeukemia, 2006
- Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myelomaBlood, 2005
- Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myelomaTransplantation and Cellular Therapy, 2004
- Poor Mobilization of Peripheral Blood Stem Cells is a Risk Factor for Worse Outcome in Lymphoma Patients Undergoing Autologous Stem Cell TransplantationLeukemia & Lymphoma, 2003
- Characterization and Outcome of “Hard to Mobilize” Lymphoma Patients Undergoing Autologous Stem Cell TransplantationLeukemia & Lymphoma, 2000
- Clinical significance of CD34+ cell dose in long-term engraftment following autologous peripheral blood stem cell transplantationBone Marrow Transplantation, 1999
- Progenitor cell yields are frequently poor in patients with histologically indolent lymphomas especially when mobilized within 6 months of previous chemotherapyBone Marrow Transplantation, 1998